

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Bio-heart Biological Technology Co., Ltd.**  
**上海百心安生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2185)**

**ANNOUNCEMENT REGARDING COMPLETION OF  
“FULL CIRCULATION” OF DOMESTIC SHARES AND  
CERTAIN UNLISTED FOREIGN SHARES OF THE COMPANY**

Reference are made to the announcements of the Company dated October 17, 2022 and January 4, 2023 (the “**Announcements**”) in relation to the official approval by the CSRC and the listing approval by the Stock Exchange regarding the implementation of the H share full circulation program of the Company.

Unless otherwise defined, capitalized terms used in this announcement shall have the same meaning as defined in the Announcements.

**COMPLETION OF THE CONVERSION AND LISTING OF DOMESTIC SHARES  
AND CERTAIN UNLISTED FOREIGN SHARES OF THE COMPANY**

The board of directors of the Company (the “**Board**”) is pleased to announce that the conversion of 100,107,425 Domestic Shares and 74,509,781 Unlisted Foreign Shares into H Shares was completed on January 13, 2023. The Converted H Shares were allotted on January 13, 2023 and the listing of the Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on January 16, 2023. The holders of the Converted H Shares who are PRC nationals can only conduct trading of the Converted H Shares subject to the completion of the onshore arrangement procedures as set out in the announcement of the Company dated January 4, 2023.

## SHARE CAPITAL STRUCTURE

Upon completion of the Conversion and Listing, the share capital structure of the Company is set out below:

Class of Shares	Immediately before completion of the Conversion and Listing		Upon completion of the Conversion and Listing	
	<i>Number of Shares</i>	<i>Approximate percentage</i>	<i>Number of Shares</i>	<i>Approximate percentage</i>
Domestic Shares	100,107,425	41.04%	–	–
Unlisted Foreign Shares	82,223,459	33.71%	7,713,678	3.16%
H Shares	61,606,116	25.25%	236,223,322	96.84%
Total number of issued Shares	243,937,000	100.00%	243,937,000	100.00%

*Note:* The percentages have been rounded off to two decimal places.

By Order of the Board  
**Shanghai Bio-heart Biological Technology Co., Ltd.**  
**Philip Li WANG**  
*Chairman and executive Director*

Shanghai, the People's Republic of China, January 13, 2023

*As at the date of this announcement, the Board of the Company comprises Mr. Philip Li WANG as Chairman and executive Director, Mr. Yunqing WANG and Ms. Peili WANG as executive Directors, Mr. Quan ZHOU and Mr. Ji CHEN as non-executive Directors, and Mr. Charles Sheung Wai CHAN, Mr. Xubo LU and Mr. George Chien Cheng LIN as independent non-executive Directors.*